Trends in Endovascular Mechanical Thrombectomy in Treatment of Acute Ischemic Stroke in the United States

• Published in: World neurosurgery Vol. 138; pp. e839 - e846
• Main Authors: MacKenzie, Isobel E.R., Moeini-Naghani, Iman, Sigounas, Dimitri
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2020
• Subjects: Endovascular; Mechanical thrombectomy; National Inpatient Survey; Stroke; Stroke; Mechanical thrombectomy; Endovascular; MT; NIS; MSA; AIS; IV; National Inpatient Survey; mRS; t-PA
• ISSN: 1878-8750; 1878-8769; 1878-8769
• DOI: 10.1016/j.wneu.2020.03.105

Numerous randomized controlled trials have shown that endovascular mechanical thrombectomy (MT) is an effective treatment for large vessel ischemic stroke. This study examines variation in rates of MT across the United States by geographic region and urban-rural areas to identify utilization disparities. Data from the Global Burden of Disease Collaborative Network were used to determine acute ischemic stroke (AIS) incidence by state for 2016. The 2016 National Inpatient Sample was accessed to identify patients who underwent MT and patients who were diagnosed with cerebral infarct due to thrombosis or embolism of anterior circulation arteries representing the AIS population of interest. National Inpatient Sample data were used to create national weighted estimates of the size of subject populations, age at admission, length of stay, and discharge status. In the United States, approximately 13,010 mechanical thrombectomies were performed in 2016, representing 3.1% of the AIS population. Proportions of patients undergoing MT were highest in large central metropolitan areas and lowest in rural settings when compared with the national estimate. East North Central and West South Central regions had significantly lower proportions of patients treated with MT. Discharge destinations, a proxy for clinical outcome, differed significantly by region and urban-rural designation. The number of MTs performed in 2016 increased approximately 1.3 times from 2015. Considering that 10%–17% of patients with AIS may be MT-eligible, current rates of MT are low across all regions, but the most pronounced disparities and poorer clinical outcomes occur in rural areas, particularly in the Northeast/Southwest regions of the Midwest.